UCB was founded in 1928 and was originally a chemicals manufacturer with a separate pharmaceuticals division. By the 1950s the focus of UCB had shifted to prescription medicines.
In 2004, UCB acquired Celltech, the UK’s leading biotechnology company, which brought expertise in antibody-based drug discovery to the company. Schwarz Pharma was acquired in 2007, bringing its own portfolio of neurology and urology products.
The UK premises of UCB are located in Slough, Berkshire. The site at Slough houses the immunology research hub and the head office for the UK commercial organisation. Antibody research and early antibody development functions are also located in Slough alongside some manufacturing and corporate functions.
There are three buildings on the Slough site, housing around 600 staff.
UCB now focuses on severe diseases within immunology and CNS.
- UCB is a top five investor in UK pharmaceutical R&D*, investing over £230 million in 2010
- Globally UCB invests more than 20% of its sales revenue into R&D
- In the UK, UCB’s R&D, Commercial and Corporate functions are located in Slough, Berkshire
- UCB employs around 600 staff in the UK, of whom about 400 are engaged in research and development activities
- The company supplies over 40 UK-approved medicines.
UCB is active in a number of therapy areas including epilepsy, movement disorders, rheumatoid arthritis and allergy. UCB’s medicines are making a real difference to the lives of people all over the world and some of our products are among the leaders in their fields.
UCB is a top five investor in biopharmaceutical R&D in the UK, investing more than 20% of its sales revenue into R&D. Around 40% of company research is now carried out in the UK.
In 2009, a new biologics R&D centre was opened at the Slough campus. The research hub in Belgium concentrates on CNS therapies while the UK research focus is on immunology. Here, UCB is researching drugs for conditions such as rheumatoid arthritis, lupus and osteoporosis. The site is renowned for its capabilities in antibody-based drug discovery and early development.
A significant number of development and regulatory milestones were achieved in 2010, creating a strong basis for the future.
* based upon data in the 2010 BIS R&D Scoreboard (BIS = Department for Business, Innovation & Skills).